 Isotrotinoin has revolutionized the treatment of acne vulgaris and is increasingly recognized as a useful therapeutic option for many other cutaneous conditions, including hydrodinitis suprativa, sebaceous gland pathology, rosacea, scarring alopecia, cosmetic dermatology, and non-melanoma skin cancer prophylaxis. Despite limited evidence from studies with low statistical power, isotrotinoin has shown potential as an adjunctive treatment or second-line agent in recalcitrant cases unresponsive to first-line therapy, if used within the correct cohort and with appropriate pretreatment counselling regarding side effects. This article was authored by Emily Forbat, Faisal Ali, and for Ross El-Naimi.